Literature DB >> 7472939

Preservation of postprandial intestinal hyperemic response after small bowel transplantation.

R Yang1, Q Liu, J L Unthank, M D Pescovitz, J L Grosfeld.   

Abstract

Postprandial intestinal hyperemia (PIH) is a normal physiological phenomenon and is thought to accommodate the increased intestinal metabolic demand during food digestion. Lack of such a response could lead to malabsorption. The purpose of this study was to determine whether transplanted intestine retains the ability to mediate PIH. Nineteen rats with syngeneic orthotopic small bowel transplantation (SBT) and 13 normal controls were further divided into two subgroups to receive gastric gavage of either 2 mL of Ensure Plus (EP) high-calorie liquid nutrition or 2 mL of normal saline. Intestinal blood flow was determined before, and 20 and 45 minutes after the gavage, employing a colored microsphere technique. The results showed that basal blood flow to the transplanted intestine (56.7 +/- 26.7 mL/min/100 g) was similar to that of normal intestine (64.2 +/- 35.8 mL/min/100 g; P > .1). EP feeding elicited a marked increase in intestinal blood flow (PIH phenomenon) in both normal and SBT animals. The magnitudes of flow increase were similar for the two groups (249 +/- 99% versus 241 +/- 76% of baseline 45 minutes after EP feeding in the normal and transplanted intestine, respectively; P > .1). The results indicate that hyperemic response to feeding is normal in syngeneic orthotopic SBT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472939     DOI: 10.1016/0022-3468(95)90348-8

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  1 in total

1.  Impact of vasoactive intestinal polypeptide and gastrin-releasing peptide on small bowel microcirculation and mucosal injury after hepatic ischemia/reperfusion in rats.

Authors:  Ingo Leister; J Sydow; T Stojanovic; L Füzesi; B Sattler; M Heuser; H Becker; P M Markus
Journal:  Int J Colorectal Dis       Date:  2004-07-27       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.